# Pfizer Announces Starna CAR-T Licensing Deal Worth Up to $2.6 Billion

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/60390
Published: 2026-11-18T12:22:46.000Z
Updated: 2026-11-18T12:22:46.000Z
Section: Business

> The exclusive agreement covers development and commercialization of chimeric antigen receptor T-cell therapies.

Pfizer announced Wednesday an exclusive CAR-T licensing deal with Starna Therapeutics valued at up to $2.6 billion, linking the New York-based drugmaker with a China-based RNA medicines company.

The agreement covers development and commercialization of chimeric antigen receptor T-cell therapies, also known as CAR-T therapies.

Starna Therapeutics is based in China. Pfizer is based in New York.


